Morepen Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Morepen Laboratories reported audited FY2026 results with consolidated total income of Rs. 1,82,700.56 lakhs and PAT of Rs. 6,212.36 lakhs, down from Rs. 11,827.41 lakhs in FY2025. Standalone revenue grew 8.4% to Rs. 1,70,269.01 lakhs but PAT fell 35% to Rs. 6,605.75 lakhs due to higher finance costs and selling expenses. The Board approved a second addendum to the Business Transfer Agreement with subsidiary Morepen Medipath Limited, revising the appointed date for hive-off of Medical Devices business to April 1, 2026, with final consideration of Rs. 19,710.12 lakhs. This is a related party transaction on arm's length basis. A final dividend of Rs. 0.20 per share was recommended. Auditors issued an unmodified opinion. Dr. Morepen Limited ceased to be a subsidiary effective July 31, 2025, after stake reduction from 80% to 19.94%.
Profit declined significantly year-on-year despite modest revenue growth in standalone numbers. The business transfer to subsidiary continues the company's restructuring but PAT dropped from Rs. 10,157.52 lakhs to Rs. 6,605.75 lakhs standalone. Shareholders should monitor elevated finance costs and selling expenses impacting profitability.